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Medium- and long-chain free fatty acids (FFAs) are energy source for whole body and
biological metabolites and components. In these decades, some research groups have
reported that the biological functions of medium- to long-chain FFAs are exerted through
G-protein coupled receptor designated free fatty acid receptor (FFAR). As the medium- to
long-chain FFAs-activated FFARs, FFA1 and FFA4 are reported to be expressed widely in
whole body and regulate various physiological processes. FFA1 expressed in pancreatic
β-cells has been shown to be involved in insulin secretion. FFA4 expressed in intestine,
adipocytes, and macrophages has been shown to be involved in incretin secretion, dif-
ferentiation, and anti-inflammatory effect, respectively. These physiological functions have
been focused on the treatment of metabolic disorders. In addition, these receptors have
been also reported to be expressed in several other tissues such as intestine for FFA1,
and tongue and stomach for FFA4. The recent functional studies indicated that they also
contributed to energy homeostasis. Further, the number of synthetic compounds of FFA1
and FFA4 strongly promoted the physiological characterization of the receptors and their
own therapeutic utility. In this article, we will discuss the recent progress regarding the
therapeutic potential of these receptors and its ligands.
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INTRODUCTION
Free fatty acids (FFAs) are known to act as the critical energy source
in the whole body. In addition, FFAs also act as signal molecules in
various physiological reactions (1, 2). As one of these mechanisms,
G-protein-coupled receptors (GPCRs) activated by FFAs desig-
nated as free fatty acid receptor (FFAR) family have played impor-
tant role especially in energy metabolism (3). Among FFAR family,
FFA1 (known as GPR40) and FFA4 (known as GPR120) are clas-
sified as medium- to long-chain fatty acid-activated receptors (4,
5). On the other hand, FFA2 and FFA3 are classified as short-chain
fatty acid-activated receptors (refer to each topic) (6, 7). In terms
of natural ligands for FFA1 and FFA4, medium- and long-chain
fatty acids that showed various physiological functions generally
and contained 6–12 and more than 12 carbon chains are mainly
provided by food digestion and lipolysis in adipose tissues. As
unsaturated fatty acids that include double bond are not supplied
in biosynthesis in human, we have to take in these unsaturated
fatty acid as food intake. A number of studies for FFA1 and FFA4
revealed that these two receptors have been contributed to regulate
energy metabolism and metabolic diseases such as type 2 diabetes
and obesity. In this review, we summarize the therapeutic utility
of medium- and long-chain fatty acid receptors, FFA1 and FFA4.
THERAPEUTIC POTENTIAL OF FFA1 AND FFA4
PHYSIOLOGICAL FUNCTIONS RELATED TO ENERGY
METABOLISM
Among FFARs, FFA1 and FFA4 are classified as medium- to long-
chain FFARs. The ligand property of these two receptors was
similar to each other; however, the expression profile is different
in several tissues (4, 5). The physiological functions of FFA1 and
FFA4 related to the energy metabolism regulation are as follows.
FFA1
Free fatty acid 1 expressed in pancreatic β-cell and intestine has
been considered to have therapeutic utility. FFA-induced glucose-
stimulated insulin secretion (GSIS) in β-cells via FFA1 has been
reported by Itoh et al. (4). Using FFA1 KO and TG mice, FFA1
exhibited protective effect against chronic and/or excess stimula-
tion of glucose-induced toxic effect on β-cells (8–10). In addition,
depolymerization of F-actin and the activation of protein kinase
D1 (PKD1) are contributed to the FFA1-mediated insulin secre-
tion from β-cells (11). Further, Flodgren et al. reported that not
only in β-cells but also α-cells also expressed FFA1 and con-
tributed to glucagon secretion (12). In intestine, FFA1 expression
was also confirmed in the gastric inhibitory polypeptide (GIP) and
glucagon like peptide-1 (GLP-1) incretin hormones secreting cells
such as the intestinal K and L cells (13, 14). In addition, intestinal I
cells that express cholecystokinin (CCK) also expressed FFA1 were
reported by Liou et al. (15). Therefore, FFA1 might regulate insulin
secretion not only in direct but also in indirect mechanism.
FFA4
Free fatty acid 4 expressed in intestine, adipose tissue, and taste
buds is considered as therapeutic target for metabolic disorders.
Similar to FFA1 expression in intestine, FFA4 is expressed in
intestinal L-cell that can secrete GLP-1 (5). In adipose tissue,
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FFA4 has been contributed to regulate adipose differentiation
and GLUT-4 translocation that regulates glucose incorporation
(16, 17). The effect of FFA4 on energy metabolism was showed
in GPR120 KO mice study (18). Further, FFA4 expressed in
macrophages was reported to regulate inflammatory responses
(17). On the other hand, in taste buds, FFA4 expression was
confirmed in type 1 and 2 taste bud cells (19, 20). Since the
FFA stimulation of these cells activated taste nerve response,
fat preferences might be regulated via FFA4. These findings
provided us the possibility for the therapeutic utility of FFA1
and FFA4.
SYNTHETIC LIGANDS AND ITS THERAPEUTIC UTILITY
FFA1
To regulate these physiological functions, more selective ligands
are expected to be developed for therapeutic candidates. For FFA1,
a number of selective agonists have been reported. The expected
pharmacological property of the compound is the selectivity com-
pared to other FFARs, the potency compared to natural ligands,
and efficacy not only in in vitro but also in in vivo experiments.
NCG75, GW9508, and TAK-875 have been reported as selective
and potent agonists. However, these compounds showed similar
effect on insulin secretion compared to the endogenous FFA lig-
ands in insulin-secreting cell line such as INS-1 and MIN6 cells
(21–23). Recently, TAK-875 has been reported to be failed in clin-
ical trial owing to the side effect such as liver toxicity. Therefore,
unknown signaling mechanisms might contribute to regulate the
physiological functions. To obtain the beneficial effect of FFA1,
we need to understand more precise mechanisms in cell line
levels.
FFA4
For FFA4, we identified a partial agonist among the natural com-
pounds derived from fruiting bodies of Albatrellus ovinus (24).
Further,we also identified a series of synthesized compounds based
on PPARγ-agonist thiazolidinediones. Among these compounds,
a selective agonist NCG21 showed selectivity for FFA4 compared
to FFA1 (25, 26). TUG-891 developed by Hudson et al. showed the
most potent agonistic activity that activated not only in G-protein
but also in β-arrestin-dependent pathways (27, 28). Metabolex was
developed as selective agonist for FFA4 and the pharmacological
properties were examined not only in cultured cells but also in
animal models (29).
In addition, isoindolin-1-one series and phenyl-isoxazol-3-ol
series developed by Banyu Pharmaceutical Co. Ltd. showed potent
selectivity for FFA4 compared to FFA1 with nanomolar order
potency (30, 31).
FURTHER CHALLENGE OF THE FFA1 AND FFA4 RESEARCH
FOR THERAPEUTIC APPLICATION
As described in previous section, the physiological and pharmaco-
logical functions of these two receptors have increasingly revealed.
The synthetic ligands that showed the usefulness not only for
in vitro but also for in vivo study have been also increased. However,
to proceed these findings to develop the pharmaceutical agents, we
should answer the several questions about the molecular mecha-
nisms of these receptors. The signal transduction mechanisms of
FIGURE 1 | Schematic diagram of the physiological function of
medium- to long-chain fatty acid receptors FFA1 and FFA4 related to
the metabolic regulation.
these two receptors have been reported that FFA1 coupled to Gq
protein but not the Gi/o or Gs, and FFA4 coupled to Gq family
and β-arrestin pathways (4, 5, 17, 32). However, the precise mech-
anism that connects a signal pathway and a specific physiological
function has not been well-understood yet. The dimerization of
receptors has been reported to regulate the affinity of the ligand,
signaling pathway, and related physiological functions (33). Since
FFARs including short-chain fatty acid receptors are expressed in
the same tissues such as pancreatic β-cells, intestine and immune
cells, the dimerization of these receptors might be formed in cell
surface, and the physiological functions of each receptor might
be regulated. On the other hand, the protein expression pro-
file should be examined more precisely because several studies
reported that the receptor expression is controversial. Although
the receptor expression in the tissues is evaluated by mRNA levels
in some studies, mRNA levels do not always reflect the protein
level. Various commercial antibodies for FFA1 and FFA4 are avail-
able, however, we should carefully validate these antibodies in
terms of selectivity since the antibodies for GPCR sometimes
lack its selectivity (34). Further, the specific agonist that shows
the selectivity for specific signaling pathway such as biased lig-
and could be useful not only for the pharmacological tool but
also for the therapeutic candidates. The adequate screening sys-
tem for each signal pathway and structure–activity relationships
of FFA1 and FFA4 ligand might be useful to develop these com-
pounds. Further using this information, we could discriminate the
beneficial effects of the FFA1 and FFA4 ligands from its adverse
effects.
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CONCLUSION
FFA1 and FFA4 regulate the energy metabolic mechanism by
acting as sensors for FFAs mainly provided by foods and lipol-
ysis. A great number of reports showed that FFA1 and FFA4 are
regulated by various physiological processes and the possibility
for the therapeutic utility for metabolic disorders (Figure 1).
However, we should reveal more precise molecular mechanisms
underling metabolic diseases regulated by these receptors. In addi-
tion, the synthetic ligands, which can show selectivity not only
among these receptors but also for the specific signals in each
receptor, are expected to be developed in the future. Therefore,
FFA1 and FFA4 may represent a promising therapeutic utility
for the treatment of metabolic syndromes, such as obesity and
diabetes.
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